Creative Biolabs' Custom Targeted LNP Synthesis Service offers proprietary lipid formulations and functionalized nanocarrier engineering to accelerate gene therapy, enabling stable, scalable, highly selective LNPs for clinical translation.
It addresses nucleic acid delivery bottlenecks, achieves high-efficacy extrahepatic targeting, solves poor selectivity and vector immunogenicity, and moves projects beyond liver-centric LNPs to treat cancer, infectious, and genetic diseases safely and efficaciously.
Discover How We Can Help - Request a ConsultationThe core mechanism of our Targeted LNP Synthesis Service lies in engineering LNP surface properties to control biodistribution and cellular uptake, achieved via two complementary approaches:
Manipulate the ratio and type of the four LNP components (especially ionizable and helper lipids) to regulate LNP interactions with plasma proteins and systemic circulation. This Selective Organ Targeting (SORT) process intrinsically shifts LNP accumulation from the liver to other desired organs.
Covalently link specific biological ligands (e.g., antibodies, peptides) to the PEG-lipid on the LNP surface. The ligand acts as a "key" to bind specifically to cell-surface receptors ("locks") on target cells, triggering receptor-mediated endocytosis for high-efficiency, cell-specific uptake. After internalization, pH-sensitive ionizable lipids enable endosomal escape, releasing the therapeutic payload into the cytoplasm.
Fig.1 Lipid nanoparticles (LNP) can target cancer stem cells.1
| Target Category | Specific Target | Modification Method | Application & Therapeutic Use |
|---|---|---|---|
| Specific Organs | Liver | Conjugate ligands targeting the asialoglycoprotein receptor (ASGPR) | Deliver siRNA/mRNA to hepatocytes for gene silencing/protein expression; e.g., treat hereditary transthyretin amyloidosis (hATTR), hepatitis, liver cancer. |
| Lungs | Modify ligands specific to lung epithelial cells (e.g., adhesion molecule antibodies) | Deliver antiviral mRNA (anti-influenza/COVID-19) or anti-inflammatory drugs; treat lung infections, chronic obstructive pulmonary disease (COPD). | |
| Spleen | Conjugate ligands targeting specific receptors on splenic dendritic cells (DCs) | Deliver vaccine antigen mRNA to activate splenic immune cells; develop tumor vaccines or infectious disease vaccines. | |
| Tumor Tissues | Modify antibodies targeting highly expressed receptors on tumor cells (e.g., HER2, EGFR) | Deliver chemotherapeutic drugs or siRNA to solid tumors (e.g., breast cancer, lung cancer); reduce normal tissue damage. | |
| Specific Cells | Immune Cells - Dendritic Cells (DCs) | Conjugate antibodies against CD11c or DEC-205 ligands | Deliver tumor antigen mRNA to activate DC antigen-presenting function; used for tumor immunotherapy. |
| Immune Cells - T Cells | Modify antibodies against CD3 or CD4 | Deliver mRNA for CAR-T cell construction; enable in vivo CAR-T generation, simplify in vitro culture. | |
| Immune Cells - Macrophages | Conjugate ligands targeting mannose receptors | Deliver anti-inflammatory small-interfering RNA; treat diseases from excessive macrophage activation (e.g., rheumatoid arthritis). | |
| Parenchymal Cells - Cardiomyocytes | Conjugate cardiac-specific peptides (e.g., antibodies against human cardiac troponin I) | Deliver cardioprotective mRNA (e.g., anti-apoptotic genes); treat acute myocardial infarction. | |
| Parenchymal Cells - Pancreatic Beta Cells | Modify ligands targeting specific receptors on pancreatic islet cells | Deliver mRNA promoting insulin synthesis; treat type 1 diabetes. | |
| Specific Physiological Locations | Central Nervous System (CNS) | Modify ligands crossing the blood-brain barrier (e.g., transferrin receptor antibodies, lactoferrin) | Deliver drugs for neurodegenerative diseases (e.g., siRNA for Alzheimer's disease); solve CNS drug delivery challenges. |
| Eyes | Conjugate ligands specific to retinal pigment epithelial (RPE) cells | Deliver anti-angiogenic drugs or gene therapy drugs; treat age-related macular degeneration (AMD), retinitis pigmentosa. | |
| Intestines | Modify adhesion ligands specific to intestinal epithelial cells | Develop oral LNP formulations; deliver probiotic regulatory factors or anti-infective mRNA; treat intestinal inflammation (e.g., ulcerative colitis). |
We provide a comprehensive and transparent process designed to move your project efficiently from concept to final LNP formulation.
Clients provide target tissue/cell type (e.g., T-cells, lung epithelial cells), nucleic acid cargo (e.g., specific mRNA sequence, RNP complex), and desired targeting moiety (if known, e.g., targeting antibody or peptide); we define target LNP characteristics (size, charge, pKa) and select initial ionizable lipid candidates.
Conduct high-throughput screening of ionizable lipid libraries and helper components; select optimal lipid ratios and preparation parameters (e.g., flow rates, pH conditions) via advanced microfluidics to achieve desired physicochemical properties (e.g., 80-150 nm particle size).
Perform precise LNP surface modification, including chemical conjugation of selected ligands (e.g., peptides, antibodies) to PEG-lipids (in situ or post-assembly); confirm ligand orientation and binding capacity to enable active targeting.
Conduct comprehensive characterization of lead LNP candidates, including measuring particle size and PDI via Dynamic Light Scattering (DLS), testing Zeta potential (surface charge), and determining nucleic acid encapsulation efficiency via UV-Vis spectroscopy.
Clients receive detailed Formulation and Characterization Reports, functionalized LNP material, and transfection efficiency data (EC50 analysis); they perform stability testing over time to provide robust shelf-life recommendations.
The typical timeframe for this service ranges from 8 to 14 weeks, depending on the complexity of the targeting moiety and the required scale of the initial formulation batch.
Creative Biolabs' Custom Targeted LNP Synthesis Service provides an integrated solution, combining chemical innovation with biological mastery to guarantee superior delivery performance tailored precisely to your therapeutic needs.
Our Advantage
Customized LNP Design
Tailor LNP lipid composition (ionizable lipids, helper lipids, cholesterol) to optimize endosomal escape and delivery efficiency, matching the specific requirements of your mRNA or CRISPR payload.
Targeting Strategy Versatility
Offer comprehensive targeting strategies, including Selective Organ Targeting (SORT) and Active Targeting via Ligand Coupling (peptides, antibodies), to achieve extrahepatic and cell-specific delivery.
Advanced Formulation Technology
Utilize microfluidic mixing for precise, controlled, and reproducible synthesis of monodisperse LNPs. These LNPs feature tight PDI and predictable scale-up behavior for consistent production.
High Encapsulation and Stability Guarantee
Optimize formulation conditions to ensure over 90% nucleic acid encapsulation efficiency. Verify in vitro and in vivo stability through rigorous QC checks to ensure product reliability.
Rigorous Quality Control Documentation
Provide high-standard quality control tools to quantify and evaluate product quality. This includes pKa measurement, Zeta potential testing, and a full component Certificate of Analysis (CoA) to support IND documentation.
Process Optimization and Transfer
Run the synthesis process in batch or continuous modes. Optimize preparation conditions to maximize yield and enable smooth technology transfer for large-scale production.
A: Ensuring functional activity is a critical step in our process. We don't just confirm chemical conjugation; we perform dedicated binding assays (ELISA, flow cytometry) after the LNP is formed to validate that the ligand maintains its correct orientation and high affinity for the target cell receptor. This guarantees that the targeted delivery is biologically active.
A: The main advantages are payload capacity and immunogenicity. Viral vectors have limited capacity and elicit a strong, persistent immune response, often preventing re-dosing. Our LNPs can carry large mRNA and RNP complexes, are biodegradable, and are engineered to minimize immune response, allowing for safe repeat administration.
A: To provide you with the most efficient proposal, we primarily need three pieces of information: the identity of your nucleic acid cargo, your target cell type or tissue, and the in vitro expression/editing data (if available). Allows us to rapidly initiate the most appropriate targeting strategy.
A: While we do not file IND applications, we provide comprehensive, traceable documentation for the materials and processes used. This includes Certificates of Analysis (CoA) detailing the purity, consistency, and stability of the LNP components and final formulation, which is essential for your CMC section in a regulatory submission.
Creative Biolabs' Custom Targeted LNP Synthesis Service delivers clinically relevant, high-fidelity non-viral delivery solutions. We specialize in engineering the physicochemical properties of LNP and their surfaces to achieve extrahepatic and cell-specific targeting, maximizing therapeutic efficacy while minimizing off-target risks.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
